Accurate imaging is crucial in focal therapy for prostate cancer. There is limited data for the prediction of cancer size using multiparametric MRI (mp-MRI). We evaluate the size correlation between mp-MRI detected and wholemount histology confirmed prostate cancer, and the impact of highgrade cancer on the size prediction for focal therapy.
INTRODUCTION AND OBJECTIVES:
Accurate imaging is crucial in focal therapy for prostate cancer. There is limited data for the prediction of cancer size using multiparametric MRI (mp-MRI). We evaluate the size correlation between mp-MRI detected and wholemount histology confirmed prostate cancer, and the impact of highgrade cancer on the size prediction for focal therapy.
METHODS: This IRB approved study (CIRB 2017 (CIRB /2651 ) enrolled all radical prostatectomies operated between 1 January 2015 to 31 July 2017. The inclusion criteria were pre-operative mp-MRI performed in our institution, either pre-biopsy or >1 year from biopsy, and available wholemount histology. Those with prior prostate cancer treatments were excluded. Each lesion was outlined on histology, with the high-grade (HG)) components (Gleason 4 and 5) colour-coded differently. Lesions on imaging were matched to histology (entire lesions and HG components), and measured at the same axial plane taking the mean of 2 readings. Spearman's rank correlation was used to compare mp-MRI and histology. Specimen shrinkage correction used the maximum transverse prostate diameter as a reference. Bland-Altman plots were used to assess size discrepancies between imaging and histology, and evaluate the adequacy of mpMRI in measuring entire lesions or HG components. Per lesion analysis was performed, with statistical significance defined as p<0.05.
RESULTS: There were 54 cases, comprising 162 lesions on either mp-MRI and histology combined. The sensitivity of mp-MRI to detect cancer was 81% (101/125), with a false positive rate of 27% (37/138). Mean prostate shrinkage was 9% (range -10 to 28 METHODS: In this randomized controlled design study, patients with localized prostate cancer were randomized either to the preference assessment intervention or to the usual care group. Patient reported outcomes (satisfaction with care, satisfaction with decision, generic and prostate-specific health related quality of life, depression and anxiety) were assessed at baseline, and at 3, 6, 12 and 24-month follow-up. Clinical data such as stage of cancer, treatment, PSA, Gleason score and comorbidity were obtained from medical charts. Preference assessment was done using our web-based adaptive conjoint analysis tool, PreProCare, prior to treatment choice. CONCLUSIONS: Preference assessment is a key component of patient-centered care and is feasible among localized prostate cancer patients. Results of our novel study showed that patient treatment choice aligned with their values. Value markers (or utility levels) of treatment such as survival, recovery time and sexual function were associated with AS among low-risk prostate cancer patients. Preference assessment intervention can help prostate cancer patients reveal their preferences, leading to better alignment with treatment decision. Future research should identify strategies to ensure diagnosis and treatment options are communicated to patients accurately, therefore reducing overtreatment and the resulting burden on healthcare systems.
